← Back to Search

CAR T-cell Therapy

CAR T Cells for Acute Lymphoblastic Leukemia

Phase 1
Recruiting
Led By Jae Park, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights
No Placebo-Only Group

Summary

"This trial involves collecting T cells from participants' white blood cells through a procedure called leukapheresis. These T cells will be modified in a lab to create the CAR T-cell therapy that participants will

Who is the study for?
This trial is for people with a type of blood cancer called Acute Lymphoblastic Leukemia (ALL), specifically those who have seen their disease return. Participants must be eligible for leukapheresis, the procedure to collect white blood cells needed to create the therapy.
What is being tested?
The study involves taking participants' T cells and modifying them in a lab to become 19-28z/IL-18 CAR T cells, which are designed to fight leukemia. The process from collection to receiving the modified cells as treatment takes about 2-4 weeks.
What are the potential side effects?
Potential side effects may include reactions related to immune system activation such as fever, fatigue, and flu-like symptoms; complications from leukapheresis; or other issues specific to CAR T-cell therapies.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Toxicity as determined by CTCAE, version 5.0

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Dose Level 3Experimental Treatment1 Intervention
1x106 cells/kg with lymphodepleting chemotherapy (LDC)
Group II: Dose Level 2Experimental Treatment1 Intervention
0.5x106 cells/kg with lymphodepleting chemotherapy (LDC)
Group III: Dose Level 1Experimental Treatment1 Intervention
0.5x106 CAR-T cell/kg without lymphodepleting chemotherapy (LDC)

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,969 Previous Clinical Trials
597,341 Total Patients Enrolled
Jae Park, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
15 Previous Clinical Trials
553 Total Patients Enrolled
~12 spots leftby Feb 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top